Pancreatic Cancer Research

ResearcherChina Medical UniversityActive in the last 2 years

Li‐Yuan Bai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7739-4077; OpenAlex author ID A5004548381. Sources: OpenAlex.

Their work

Papers
24 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
69
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 8 papers · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 5 papers

Papers 24

  1. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). Co-author DOI 10.1016/j.ejca.2026.116229↗
  2. Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort. Last author DOI 10.1016/j.jfma.2026.04.039↗
  3. Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort… Last author DOI 10.1016/j.jfma.2026.05.008↗
  4. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-026-72271-5↗
  5. Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Ph… Co-author DOI 10.1158/1078-0432.ccr-26-0805↗
  6. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  7. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Co-author DOI 10.1016/j.bj.2023.100696↗
  8. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.03.014↗
  9. All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer First author DOI 10.1101/2024.10.20.619300↗
  10. Circulating tumor cells positivity provides an early detection of recurrence of pancreatic cancer First author DOI 10.1016/j.jfma.2023.01.012↗
  11. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers15041008↗
  12. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovo… Co-author DOI 10.1002/jhbp.1128↗
  13. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - T… Co-author DOI 10.1016/j.ejca.2022.06.043↗
  14. Endoscopic ultrasound-guided fine-needle biopsy as a tool for studying the intra-tumoral microbiome in pancreatic ductal adenocarcinoma: a pilot study. Co-author DOI 10.1038/s41598-021-04095-w↗
  15. Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.3389/fimmu.2022.870406↗
  16. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Co-author DOI 10.3389/fonc.2022.800842↗
  17. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Co-author PMID 35530292↗
  18. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma rec… Co-author PMID 36225629↗
  19. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic duc… Co-author PMID 36504882↗
  20. Intraperitoneal nivolumab in a patient with pancreatic cancer and refractory malignant ascites. Last author DOI 10.1016/j.ejca.2021.01.045↗
  21. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2021.1973710↗
  22. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. Co-author DOI 10.1177/17588359211058255↗
  23. Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-cente… Last author DOI 10.1371/journal.pone.0244487↗
  24. OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling. First author DOI 10.18632/oncotarget.16450↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yung‐Yeh Su · 13 shared papers, 2020–2026 · strength 2.17
  2. Chung‐Pin Li · 13 shared papers, 2021–2026 · strength 2.14
  3. Shih‐Hung Yang · 13 shared papers, 2021–2026 · strength 2.06
  4. Tai‐Jan Chiu · 12 shared papers, 2021–2026 · strength 2.00
  5. Nai‐Jung Chiang · 13 shared papers, 2020–2026 · strength 1.94
  6. Wen‐Chi Chou · 12 shared papers, 2021–2026 · strength 1.93
  7. Jen‐Shi Chen · 11 shared papers, 2021–2026 · strength 1.64
  8. Yan‐Shen Shan · 11 shared papers, 2021–2026 · strength 1.63
  9. Li‐Tzong Chen · 11 shared papers, 2020–2026 · strength 1.62
  10. Yen‐Yang Chen · 10 shared papers, 2021–2024 · strength 1.39
  11. Cheng‐Ming Peng · 8 shared papers, 2021–2024 · strength 1.06
  12. I‐Wei Ho · 3 shared papers, 2026 · strength 0.75
  13. Hsiu-Tzu Wang · 3 shared papers, 2023–2026 · strength 0.70
  14. Mien‐Chie Hung · 3 shared papers, 2022–2026 · strength 0.52
  15. Ching-Fei Li · 2 shared papers, 2024–2026 · strength 0.37
  16. Yongkun Wei · 2 shared papers, 2024–2026 · strength 0.37
  17. Jianhua Ling · 2 shared papers, 2024–2026 · strength 0.37
  18. Ying‐Nai Wang · 2 shared papers, 2024–2026 · strength 0.37
  19. Jie Fu · 2 shared papers, 2024–2026 · strength 0.37
  20. Haoqiang Ying · 2 shared papers, 2024–2026 · strength 0.37
  21. Paul J. Chiao · 2 shared papers, 2024–2026 · strength 0.37
  22. Dihua Yu · 2 shared papers, 2024–2026 · strength 0.37
  23. Anirban Maitra · 2 shared papers, 2024–2026 · strength 0.37
  24. Bang‐Bin Chen · 2 shared papers, 2021–2022 · strength 0.31
  25. Sung‐Hsin Kuo · 2 shared papers, 2021–2022 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.